Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species
MDM2 (T309G) polymorphism may not be directly associated with the risk of breast cancer occurrence in north Indian breast cancer patients, but it may play role in disease progression by triggering TP53 (show TP53 ELISA Kits)
The combination of MDM2 and MDM4 (show MDM4 ELISA Kits) expression is an independent predictor in patients undergoing radical cystectomy for muscle-invasive bladder cancer.
MDM2 may be used in those tumours as a marker.
The frequency of Mdm2 SNIP309 G/G in a Thai population is very low.
Increased expression of MDM2 is associated with colorectal cancer.
Results showed that 18% of esophageal cancer (EC) demonstrated moderately elevated MDM2 copy numbers which may not affect overall MDM2 overexpression in the tumor. However, 6.3% of all EC showed a strong enhancement of MDM2 gene copies, that was linked to a clusterlike amplification pattern by FISH and to strong MDM2 protein level.
results obtained from the combination of SNPs 344T>A of MDM2 and 72 Arg/Pro of p53 (show TP53 ELISA Kits), do not support the hypothesis of the prominent role of common p53 (show TP53 ELISA Kits) and MDM2 variations in the genetic mechanisms of chemotherapy resistance in breast cancer
We also observed that a dedifferentiated osteosarcomas (OS)harboring MDM2 amplification did not carry any other mutations. This study suggests that bone oncogenesis driven by TP53 (show TP53 ELISA Kits) or RB1 (show RB1 ELISA Kits) mutations occurs on a background of relative genetic stability and that the dedifferentiated OS subtype represents a clinico-pathological entity with distinct oncogenic mechanisms
Data show that the c-mdm2 proto-oncogene (show RAB1A ELISA Kits) protein (MDM2) single nucleotide polymorphism SNP309 T/T allele indicated a significant contribution to age at time of surgery.
described that strong MDM2 immunoexpression in follicular dendritic cell sarcomas can be a major diagnostic pitfall
Inactivation of Mdm2 in sertoli cells triggers p53 (show TP53 ELISA Kits) activation and apoptosis as early as 15.5 days post conception with a significant increase in apoptosis.
These findings elucidate a critical role of Mdm2-p53-Nedd4-2 signaling underlying the regulation of neural network synchrony and seizure susceptibility.
These studies demonstrate that Mdm2 holds promise as a therapeutic target in combination with conventional therapy and may lead to new clinical therapies for Triple-negative breast cancers .
there is a fine tuned balance in the interaction of ribosomal proteins with the MDM2/p53 (show TP53 ELISA Kits) axis which is important in normal hematopoiesis.
Study showed that demonstrate that Mdm2 intertwines the mammalian target of RAPA (show TRERF1 ELISA Kits), mTOR (show FRAP1 ELISA Kits), and the receptor kinase GRK2 (show ADRBK1 ELISA Kits) in regulating the desensitization/inactivation of the GPR17 (show GPR17 ELISA Kits) receptor
MDM2 mediates p73 (show ARHGAP24 ELISA Kits) ubiquitination
MDM2 supports the PRC2 mediated repression of lineage-specific genes in stem cells, independent of p53 (show TP53 ELISA Kits).
physiological activation of the 5S RNP (show RNPC3 ELISA Kits)-Mdm2-p53 (show TP53 ELISA Kits) pathway may contribute to functional decline of the hematopoietic system in a cell-autonomous manner over time.
Ribosomal proteins L11 (show RPL11 ELISA Kits) and L5 activate TAp73 (show TP73 ELISA Kits) by overcoming MDM2 inhibition.
The Mdm2(SNP309-)(G) allele significantly impacts CRC (show SCRIB ELISA Kits) through mechanisms outside the p53 (show TP53 ELISA Kits) pathway.
This gene is a target gene of the transcription factor tumor protein p53. The encoded protein is a nuclear phosphoprotein that binds and inhibits transactivation by tumor protein p53, as part of an autoregulatory negative feedback loop. Overexpression of this gene can result in excessive inactivation of tumor protein p53, diminishing its tumor suppressor function. This protein has E3 ubiquitin ligase activity, which targets tumor protein p53 for proteasomal degradation. This protein also affects the cell cycle, apoptosis, and tumorigenesis through interactions with other proteins, including retinoblastoma 1 and ribosomal protein L5. More than 40 different alternatively spliced transcript variants have been isolated from both tumor and normal tissues.
E3 ubiquitin-protein ligase Mdm2
, Mdm2, p53 E3 ubiquitin protein ligase homolog
, Mdm2, transformed 3T3 cell double minute 2, p53 binding protein
, double minute 2, human homolog of; p53-binding protein
, oncoprotein Mdm2
, double minute 2 protein
, p53-binding protein Mdm2